BESIVANCE provides powerful in vitro potency against ocular pathogens for the treatment of bacterial conjunctivitis caused by susceptible isolates1*
- Potent, broad-spectrum bactericidal activity2
- Sustained drug delivery with Durasite® technology increases residence time on the ocular surface3,4
- One dose provided 12-hour tear concentrations exceeding the MIC90 for a
broad range of ocular pathogens4-6
- Lower MIC90 values provide powerful potency1
- Flexible dosing: 1 drop, 3 times daily, 4 to 12 hours apart, for 7 days2
Study Design: BESIVANCE was administered as a topical ocular instillation to human subjects as part of a single-center, open-label study (N=64). At predetermined intervals after dosing, ocular tear samples were collected and analyzed for besifloxacin levels.4 MIC90 values for P aeruginosa, S aureus, S pneumoniae, MRSE, MRSA, MSCoNS, MRCoNS, and H influenzae are from the ARMOR 2015 surveillance study.6 MIC90 values for S epidermidis are from the BESIVANCE clinical development program.5
*ARMOR Surveillance Study, 10-year update.1 Clinical significance of these in vitro data has not been established.
MIC90 is the minimum inhibitory concentration that inhibits the growth of 90% of indicated isolates.
See what's behind the potent, broad-spectrum bactericidal activity of BESIVANCE.
Indication
BESIVANCE® (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*
*Efficacy for this organism was studied in fewer than 10 infections.
Important Safety Information
- BESIVANCE is not for injection into the eye.
- As with other anti-infectives, prolonged use of BESIVANCE may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
- Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE.
- The most common adverse event reported in approximately 2% of patients treated with BESIVANCE was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
- Safety and effectiveness in infants below one year of age have not been established.
Click here for full Prescribing Information for BESIVANCE.
References: 1. Asbell PA, Sanfilippo CM, Sahm DF, DeCory HH. Trends in antibiotic resistance among ocular microorganisms in the United States from 2009 to 2018. JAMA Ophthalmol. 2020;138(5):439-450. doi:10.1001/jamaophthalmol.2020.0155 2. BESIVANCE Prescribing information. Bausch & Lomb Incorporated; Rev. 2020. 3. Mah FS, Sanfilippo SM. Besifloxacin: efficacy and safety in treatment and prevention of ocular bacterial infections. Ophthalmol Ther. 2016;5(1):1-20. doi:10.1007/s40123-016-0046-6 4. Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009;25(4):335-344. doi:10.1089/jop.2008.0116 5. Data on file, Bausch & Lomb Incorporated. 6. Asbell PA, Sanfilippo CM, Pillar CM, DeCory H, Sahm DF, Morris TW. Antibiotic resistance among ocular pathogens in the United States. Five-year results from the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study. JAMA Ophthalmol. 2015;133(12):1445-1454. doi:10.1001/jamaophthalmol.2015.3888
Indication
BESIVANCE® (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*
*Efficacy for this organism was studied in fewer than 10 infections.
Important Safety Information
- BESIVANCE is not for injection into the eye.
- As with other anti-infectives, prolonged use of BESIVANCE may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
- Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE.
- The most common adverse event reported in approximately 2% of patients treated with BESIVANCE was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
- Safety and effectiveness in infants below one year of age have not been established.
Click here for full Prescribing Information for BESIVANCE.
THIS WEBSITE IS INTENDED FOR U.S. HEALTHCARE PROFESSIONALS ONLY.
Please choose an option below: